Description
CJC-1295 without DAC + Ipamorelin Blend combines two well-studied growth hormone axis research peptides at 5mg each. CJC-1295 without DAC (Modified GRF 1-29) acts at the GHRH receptor, while Ipamorelin selectively activates the ghrelin receptor (GHSR1a). Together this research blend is one of the most-studied combinations for investigating combined GHRH and GHS receptor activation in laboratory models.
The complementary receptor targets of CJC-1295 and Ipamorelin make this blend a frequently-cited research tool in selective growth hormone axis pharmacology.
Research areas studied
- Combined GHRH + GHS receptor research
- Selective growth hormone axis studies
- Comparative blend pharmacology research
Quality assurance
- HPLC verified at 99%+ purity
- Certificate of Analysis (COA) available upon request
- Lyophilized in a research-grade facility under controlled conditions
For research purposes only. Not for human consumption, diagnostic, or therapeutic use.